PURPOSE: To evaluate the efficacy, predictability, and safety of laser in situ keratomileusis (LASIK) for the correction of myopia and myopic astigmatism using the SCHWIND Amaris 1050RS excimer laser (SCHWIND eye-tech-solutions). METHODS: This was a prospective cohort study of 1,420 eyes with myopia or myopic astigmatism that underwent LASIK in a single tertiary center between January 2017 and April 2022. The IntraLase iFS femtosecond laser (Johnson & Johnson Vision) was used for flap creation and excimer laser ablation was performed using the SCHWIND Amaris 1050RS with aspheric aberration-free ablation profile, asymmetric pupillary offset, and seven-dimensional eye tracking. Preoperative mean spherical equivalent was -5.81 ± 2.41 diopters (D) (range: -0.63 to -13.63 D). RESULTS: At 3 months, 95.1% and 99.6% of eyes achieved uncorrected distance visual acuity of 20/20 and 20/40 or better, respectively. The mean efficacy index was 0.99 ± 0.06 and the mean safety index was 1.0 ± 0.02. For predictability, 97.7% and 99.7% of eyes were within ±0.50 and ±1.00 D of the intended correction, respectively. The mean postoperative spherical equivalent was +0.02 ± 0.21 D, mean cylinder was 0.13 ± 0.25 D, mean vector-analyzed magnitude of cylindrical error was 0.09 ± 0.22 D, mean cylindrical angle of error was 0.64 ± 6.79 degrees, and mean cylindrical vector difference was 0.15 ± 0.26 D. None had significant surgical complications. CONCLUSIONS: This study demonstrates excellent efficacy, predictability, and safety of the SCHWIND Amaris 1050RS excimer laser for the correction of myopic astigmatism. The seven-dimensional eye tracker was effective in compensating for eye movements intraoperatively.